EUVIMEDEUVIMED entdecken
Crossref

Maternal and Cord Anti-SARS-CoV-2-Spike IgG following COVID-19 Vaccination versus Infection during Pregnancy: A Prospective Study, Israel October 2021–March 2022

Raneen Abu Shqara iD, Maya Frank Wolf, Susana Mikhail Mustafa, Inshirah Sgayer, Tikva Assulyn, Abdallah Abu Zraki, Nadine Askhar Majadla, Hagai Rechnizter, Mona Shehadeh, Vered Fleisher Sheffer, Mor Bordeynik-Cohen, Orly Yakir und 4 weitere

American Journal of Perinatology · 01.05.2024 · 41 (S 01 S 01) · e1935-e1943

DOI: 10.1055/a-2090-5402 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Perinatology, erschienen am 01.05.2024. Verfasst von Raneen Abu Shqara und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Galilee Medical Center, Nahariya, Israel. Hauptthemen laut MEDLINE: COVID-19, Immunoglobulin G, COVID-19 Vaccines, SARS-CoV-2. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 16 Literaturangaben. Gefördert von: Israeli Ministry of Health supported this work.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Defining how pregnant women respond to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and vaccination is critical to optimize vaccination strategies that protect mother and infant at the epidemic. This study aimed to compare anti-SARS-CoV-2-spike immunoglobulin G (IgG) of vaccinated versus infected women and to determine the optimal timing of maternal vaccination during pregnancy at the time of epidemic. Study Design We collected maternal/cord blood at delivery (October 2021–March 2022) and measured anti-SARS-CoV-2-spike IgG geometric mean concentrations (IgG-GMCs) using a quantitative immunoassay. We compared groups according to timing and number of doses and correlated maternal and fetal IgG levels. We described the proportion of women with IgG levels above the 150 AU/mL positivity threshold according to the timing of infection/vaccination and performed a subanalysis for maternal IgG-GMC levels pre- and during the Omicron wave.

Results

We included 238 vaccinated women, 125 who received two doses and 113 three doses, and 48 unvaccinated infected women. All groups infected/vaccinated in the second or third trimester had an IgG-GMC above the positivity threshold. Third-trimester vaccination (second/third dose) resulted in higher maternal and cord-blood IgG-GMC compared to the second trimester (maternal-IgG: 102,32 vs. 4,325 AU/mL, p < 0.001; cord-IgG: 12,113 vs. 8,112 AU/mL, p < 0.001). Compared with infected-only women, a higher proportion of vaccinated women with ≥2 doses and their newborns had IgG levels above the positivity threshold at all time points. In vaccinated women, there were higher maternal IgG-GMC levels during the Omicron wave than pre-Omicron.

Conclusion

At the time of epidemic, receiving an additional COVID-19 vaccine dose in the third trimester resulted in a higher IgG-GMC compared to the second trimester. Relatively higher levels of maternal and cord IgG-GMC were achieved following vaccination than infection. Women infected during or before the first trimester might benefit from an additional third-trimester dose to prevent peripartum infection and to passively immunize their newborn. The higher levels of maternal IgG-GMC in the Omicron period are suggestive of hybrid immunity. Key Points

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Immunoglobulin GCOVID-19 VaccinesSARS-CoV-2Fetal BloodPregnancy Complications, InfectiousAntibodies, ViralHumansFemalePregnancyProspective StudiesAdultIsraelSpike Glycoprotein, CoronavirusVaccinationInfant, Newborn

Substanzen

Immunoglobulin GCOVID-19 VaccinesAntibodies, ViralSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Galilee Medical Center, Nahariya, Israel.
  • Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel.

ORCID-Profile: Raneen Abu Shqara, Amiel A Dror

Förderung

  • Israeli Ministry of Health supported this work

Zitieren

APA

Abu Shqara, R., Frank Wolf, M., Mikhail Mustafa, S., Sgayer, I., Assulyn, T., Abu Zraki, A., Askhar Majadla, N., Rechnizter, H., Shehadeh, M., Fleisher Sheffer, V., Bordeynik-Cohen, M., Yakir, O., Lowenstein, L., Sela, E., Edelstein, M., & Dror, A. A. (2024). Maternal and Cord Anti-SARS-CoV-2-Spike IgG following COVID-19 Vaccination versus Infection during Pregnancy: A Prospective Study, Israel October 2021–March 2022. American Journal of Perinatology, 41(S 01 S 01), e1935-e1943. https://doi.org/10.1055/a-2090-5402

Vancouver

Abu Shqara R, Frank Wolf M, Mikhail Mustafa S, Sgayer I, Assulyn T, Abu Zraki A, et al. Maternal and Cord Anti-SARS-CoV-2-Spike IgG following COVID-19 Vaccination versus Infection during Pregnancy: A Prospective Study, Israel October 2021–March 2022. American Journal of Perinatology. 2024;41(S 01 S 01):e1935-e1943. doi:10.1055/a-2090-5402

BibTeX
@article{AbuShqara2024,
  author = {Abu Shqara, Raneen and Frank Wolf, Maya and Mikhail Mustafa, Susana and Sgayer, Inshirah and Assulyn, Tikva and Abu Zraki, Abdallah and Askhar Majadla, Nadine and Rechnizter, Hagai and Shehadeh, Mona and Fleisher Sheffer, Vered and Bordeynik-Cohen, Mor and Yakir, Orly and Lowenstein, Lior and Sela, Eyal and Edelstein, Michael and Dror, Amiel A},
  title = {Maternal and Cord Anti-SARS-CoV-2-Spike IgG following COVID-19 Vaccination versus Infection during Pregnancy: A Prospective Study, Israel October 2021–March 2022},
  journal = {American Journal of Perinatology},
  year = {2024},
  volume = {41},
  number = {S 01 S 01},
  pages = {e1935--e1943},
  doi = {10.1055/a-2090-5402}
}
Kostenlos starten →